MX2022005376A - Moleculas de fusion del dominio extracelular (ecd) de la lectina 9 similar a inmunoglobulina que se une al acido sialico (siglec-9) y metodos de uso de las mismas. - Google Patents

Moleculas de fusion del dominio extracelular (ecd) de la lectina 9 similar a inmunoglobulina que se une al acido sialico (siglec-9) y metodos de uso de las mismas.

Info

Publication number
MX2022005376A
MX2022005376A MX2022005376A MX2022005376A MX2022005376A MX 2022005376 A MX2022005376 A MX 2022005376A MX 2022005376 A MX2022005376 A MX 2022005376A MX 2022005376 A MX2022005376 A MX 2022005376A MX 2022005376 A MX2022005376 A MX 2022005376A
Authority
MX
Mexico
Prior art keywords
siglec
methods
fusion molecules
ecd fusion
ecds
Prior art date
Application number
MX2022005376A
Other languages
English (en)
Inventor
Jeonghoon Sun
Hua Long
Spencer Liang
Rashmi Bankoti
Samuel Nalle
Original Assignee
Alector Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alector Llc filed Critical Alector Llc
Publication of MX2022005376A publication Critical patent/MX2022005376A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4726—Lectins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Recrystallisation Techniques (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • External Artificial Organs (AREA)

Abstract

La presente descripción se refiere generalmente al ECD de Siglec-9 o moléculas de fusión del ECD de Siglec-9, y a métodos de tratamiento que usan ECD de Siglec-9 y moléculas de fusión del ECD de Siglec-9.
MX2022005376A 2019-11-04 2020-11-03 Moleculas de fusion del dominio extracelular (ecd) de la lectina 9 similar a inmunoglobulina que se une al acido sialico (siglec-9) y metodos de uso de las mismas. MX2022005376A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962930227P 2019-11-04 2019-11-04
US202063014940P 2020-04-24 2020-04-24
US202063092753P 2020-10-16 2020-10-16
PCT/US2020/058687 WO2021091885A2 (en) 2019-11-04 2020-11-03 Siglec-9 ecd fusion molecules and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2022005376A true MX2022005376A (es) 2022-05-19

Family

ID=73598983

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022005376A MX2022005376A (es) 2019-11-04 2020-11-03 Moleculas de fusion del dominio extracelular (ecd) de la lectina 9 similar a inmunoglobulina que se une al acido sialico (siglec-9) y metodos de uso de las mismas.

Country Status (17)

Country Link
US (1) US11987612B2 (es)
EP (1) EP4055031A2 (es)
JP (1) JP2022553571A (es)
KR (1) KR20220092918A (es)
CN (1) CN114667298A (es)
AU (1) AU2020378251A1 (es)
BR (1) BR112022008321A2 (es)
CA (1) CA3155345A1 (es)
CL (1) CL2022001130A1 (es)
CO (1) CO2022005587A2 (es)
CR (1) CR20220244A (es)
EC (1) ECSP22044316A (es)
IL (1) IL292499A (es)
MX (1) MX2022005376A (es)
PE (1) PE20221271A1 (es)
TW (1) TW202132329A (es)
WO (1) WO2021091885A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023522251A (ja) 2020-04-24 2023-05-29 バイエル・アクチエンゲゼルシヤフト 免疫活性化のためのｄｇｋｚｅｔａ阻害剤としての置換アミノチアゾール類
WO2024102635A1 (en) * 2022-11-07 2024-05-16 Alector Llc Uses of siglec-9 ecd fusion molecules in cancer treatment

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
US20040119010A1 (en) 2002-11-01 2004-06-24 The Regents Of The University Of Colorado Quantitative analysis of protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry
CN101248089A (zh) 2005-07-01 2008-08-20 米德列斯公司 抗程序性死亡配体1（pd-l1）的人单克隆抗体
GB0521991D0 (en) 2005-10-28 2005-12-07 Univ Dundee Siglec-9 binding agents
US20070244038A1 (en) 2006-04-12 2007-10-18 The Regents Of The University Of California Methods for treating lymphocyte-associated disorders by modulation of siglec activity
DK2699264T3 (en) 2011-04-20 2018-06-25 Medimmune Llc ANTIBODIES AND OTHER MOLECULES BINDING B7-H1 AND PD-1
DK2785375T3 (da) 2011-11-28 2020-10-12 Merck Patent Gmbh Anti-pd-l1-antistoffer og anvendelser deraf
AU2012355435A1 (en) 2011-12-21 2014-07-17 Amgen Inc. Variant Fc-polypeptides with enhanced binding to the neonatal Fc receptor
JP6403062B2 (ja) 2012-12-21 2018-10-10 国立大学法人徳島大学 組織修復活性組成物及びその利用
WO2014120642A1 (en) 2013-01-30 2014-08-07 The General Hospital Corporation Diagnosis and treatment of hepatorenal syndrome
WO2016038064A1 (en) 2014-09-10 2016-03-17 Innate Pharma Cross reactive siglec antibodies
KR102434330B1 (ko) 2015-05-01 2022-08-22 더 리전츠 오브 더 유니버시티 오브 캘리포니아 글리칸 의존성 면역치료 분자
CA3003458A1 (en) 2015-10-29 2017-05-04 Alector Llc Anti-siglec-9 antibodies and methods of use thereof
US10634656B2 (en) 2015-10-30 2020-04-28 Hach Company Storage stable standards for aqueous chlorine analysis
AU2016354924A1 (en) * 2015-11-17 2018-06-21 Innate Pharma Siglec-10 antibodies
AU2017207807A1 (en) 2016-01-12 2018-07-12 Palleon Pharmaceuticals Inc. Use of Siglec-7 or Siglec-9 antibodies for the treatment of cancer
US11078274B2 (en) 2016-03-08 2021-08-03 Innate Pharma Siglec neutralizing antibodies
GB201611535D0 (en) 2016-07-01 2016-08-17 King's College London Methods and compositions for treating cancer with siglec-9 activity modulators
CA3026588A1 (en) 2016-07-01 2018-01-04 The Board Of Trustees Of The Leland Stanford Junior University Inhibitory immune receptor inhibition methods and compositions
WO2019011855A1 (en) 2017-07-10 2019-01-17 Innate Pharma ANTIBODIES NEUTRALIZING SIGLEC-9
EP3652207A1 (en) 2017-07-10 2020-05-20 Innate Pharma Combination therapy using antibody to human siglec-9 and antibody to human nkg2a for treating cancer
EP3802582A4 (en) 2018-06-07 2022-06-15 Palleon Pharmaceuticals Inc. MULTIMERIC PROTEINS FOR DETECTING A CARBOHYDRATE AND/OR TREATMENT OF A SIGLEC MEDIATED DISORDER
KR20210040948A (ko) 2018-06-29 2021-04-14 베르조 테라퓨틱스, 아이엔씨. 단핵구 및 대식세포의 염증성 표현형을 조절하기 위한 조성물 및 방법, 그리고 이의 면역요법 용도
KR20210070301A (ko) 2018-10-02 2021-06-14 오비아이 파머 인코퍼레이티드 종양 치료제와 조합한 항-ssea-4 항체를 사용하는 병용 요법
US20220211831A1 (en) 2019-04-17 2022-07-07 Bar-Ilan University Siglec-based chimeric polypeptides and uses thereof
JP2022535417A (ja) 2019-06-04 2022-08-08 ヴェルソー セラピューティクス， インコーポレイテッド 骨髄細胞炎症性表現型を調節するための抗ｓｉｇｌｅｃ－９組成物及び方法、ならびにその使用
US20220283165A1 (en) 2019-07-12 2022-09-08 The Board Of Trustees Of The Leland Stanford Junior University Methods of Enhancing Immunogenicity of Cancers

Also Published As

Publication number Publication date
CL2022001130A1 (es) 2023-02-24
US20210284710A1 (en) 2021-09-16
ECSP22044316A (es) 2022-07-29
CN114667298A (zh) 2022-06-24
KR20220092918A (ko) 2022-07-04
BR112022008321A2 (pt) 2022-07-26
US11987612B2 (en) 2024-05-21
JP2022553571A (ja) 2022-12-23
PE20221271A1 (es) 2022-09-01
TW202132329A (zh) 2021-09-01
CR20220244A (es) 2022-06-28
IL292499A (en) 2022-06-01
CO2022005587A2 (es) 2022-07-29
CA3155345A1 (en) 2021-05-14
WO2021091885A3 (en) 2021-06-17
EP4055031A2 (en) 2022-09-14
WO2021091885A2 (en) 2021-05-14
AU2020378251A1 (en) 2022-05-26

Similar Documents

Publication Publication Date Title
MX2021005887A (es) Compuestos de 2-formil-3-hidroxifeniloximetilo capaces de modular hemoglobina.
PH12019501575A1 (en) ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFá1 INHIBITORS AND USE THEREOF
PH12020552229A1 (en) Il-11ra antibodies
MX2023001527A (es) Compuestos con actividad inductora de ferroptosis y metodos de uso de estos.
JOP20200309A1 (ar) أجسام مضادة لـ il-11
MX2022007754A (es) Nuevos agonistas de il2 y metodos de uso de estos.
MX2020005567A (es) Metodos de tratamiento con asparaginasa.
WO2019040106A3 (en) COMPOUNDS, RELATED SALTS AND METHODS FOR THE TREATMENT OF DISEASES
PH12020551144A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12018501443A1 (en) Methods of administering hepcidin
CR20210620A (es) Moduladores de cot y métodos de uso de los mismos
WO2018209022A3 (en) Methods of treating neuropsychiatric disorders
MX2022005376A (es) Moleculas de fusion del dominio extracelular (ecd) de la lectina 9 similar a inmunoglobulina que se une al acido sialico (siglec-9) y metodos de uso de las mismas.
MX2022005132A (es) Terapia combinada con formulaciones de anticuerpos anti-pvrig y anticuerpos anti-pd-1.
MX2020009902A (es) Anticuerpos con especificidad dual para pd-l1 y pd-l2 humanos y metodos de uso de los mismos.
PH12018502381A1 (en) Dihydrotestosterone and dihydrotestosterone derivatives and promoters in the treatment of cancer
EA202090266A1 (ru) Ингибиторы mpo для применения в медицине
WO2019016597A3 (en) SYNTHETIC PROTEINS AND THEIR THERAPEUTIC USES
AU2016334102A8 (en) CRMP2 SUMOylation inhibitors and uses thereof
WO2020109233A3 (en) Trmt2a inhibitors for use in the treatment of polyglutamine diseases
BR112021014566A2 (pt) Moduladores de gpr35
PH12019501358A1 (en) Methods of administering hepcidin
MX2019014090A (es) Métodos para el tratamiento de la reservoritis crónica.
MX2023005591A (es) Metodos de tratamiento de enfermedades y trastornos.
ZA202104786B (en) Deutetrabenazine for the treatment of dyskinesia in cerebral palsy